Loading...
•
Dec 31, 2025
Argenx Q4 2025 Earnings Report
argenx reported strong fourth quarter 2025 results with significant growth in VYVGART net sales and solid profitability.
Key Takeaways
For the fourth quarter ended December 31, 2025, argenx generated total operating income of 1322155000 and product net sales of 1285711000, primarily driven by VYVGART. Operating profit reached 367611000 and profit for the period was 532950000, with diluted EPS of 8.02.
Product net sales reached 1285711000 in Q4 2025.
Total operating income was 1322155000 for the quarter.
Operating profit was 367611000.
Diluted EPS was 8.02 for Q4 2025.
Revenue by Segment
Forward Guidance
argenx highlighted continued expansion in 2026, including regulatory milestones, label expansions and pipeline advancement across multiple indications.
Positive Outlook
- PDUFA target action date for seronegative gMG on May 10, 2026.
- Planned sBLA submission to expand VYVGART into ocular MG.
- Topline results for ADVANCE-NEXT in primary ITP expected in Q4 2026.
- Progression of multiple Phase 3 and earlier-stage pipeline programs.
- VYVGART SC autoinjector expected to launch in 2027.
Challenges Ahead
- Forward-looking statements subject to clinical and regulatory risks.
- Dependence on continued VYVGART commercial performance.
- Ongoing R&D investments increasing operating expenses.
- Regulatory approval timing uncertainty.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...